Indonesia approves emergency use of China's mRNA COVID-19 vaccine

STORY: Indonesia approves emergency use of China's mRNA COVID-19 vaccine DATELINE: Oct. 1, 2022 LENGTH: 0:01:17 LOCATION: Jakarta CATEGORY: HEALTH/MEDICINE SHOTLIST: 1. STANDUP (English): SUN LEI, Xinhua correspondent 2. various of press release 3. SOUNDBITE 1 (English): PENNY LUKITO, Head of Indonesia's Food and Drug Monitoring Agency (BPOM) 4. SOUNDBITE 2 (English): ANDREAS DONNY, PT Etana Biotechnologies Indonesia 5. various of mRNA vaccine 6. various of BPOM STORYLINE: The Indonesian food and drug administration (BPOM) has issued an emergency use authorization (EUA) for the mRNA-platform COVID-19 vaccine, AWcorna, developed by Chinese companies. STANDUP (English): SUN LEI, Xinhua correspondent "The Indonesian food and drug authority BPOM has authorized a China-made mRNA vaccine for emergency use in individuals 18 years of age or above, as either primary or booster dose." AWcorna is a SARS-CoV-2 mRNA vaccine developed by Suzhou Abogen Biosciences Co., Ltd. with the participation of Walvax Biotechnolog

Walvax Biotech

Walvax Biotech

A photo taken on April 15, 2021 shows Walvax Biotech participating in the China International Technology Import and Export Fair in Shanghai, China. On April 27, 2021, Waston disclosed the first quarter of 2021, the listed company achieved revenue of 434 million yuan, a year-on-year increase of 286.45%, Walvax pointed out that the growth in performance was mainly due to the independent vaccine product sales income and sales achieved a large increase.

Walvax Biotech

Walvax Biotech

A photo taken on April 15, 2021 shows Walvax Biotech participating in the China International Technology Import and Export Fair in Shanghai, China. On April 27, 2021, Waston disclosed the first quarter of 2021, the listed company achieved revenue of 434 million yuan, a year-on-year increase of 286.45%, Walvax pointed out that the growth in performance was mainly due to the independent vaccine product sales income and sales achieved a large increase.

Walvax Biotech

Walvax Biotech

A photo taken on April 15, 2021 shows Walvax Biotech participating in the China International Technology Import and Export Fair in Shanghai, China. On April 27, 2021, Waston disclosed the first quarter of 2021, the listed company achieved revenue of 434 million yuan, a year-on-year increase of 286.45%, Walvax pointed out that the growth in performance was mainly due to the independent vaccine product sales income and sales achieved a large increase.

Walvax Biotech

Walvax Biotech

A photo taken on April 15, 2021 shows Walvax Biotech participating in the China International Technology Import and Export Fair in Shanghai, China. On April 27, 2021, Waston disclosed the first quarter of 2021, the listed company achieved revenue of 434 million yuan, a year-on-year increase of 286.45%, Walvax pointed out that the growth in performance was mainly due to the independent vaccine product sales income and sales achieved a large increase.